

Human domainome 1: A valuable resource for biomedical research and therapeutic development – a systematic review

Sudhir Singh^{1*}, Jigar Manilal Haria², Reena Rani³, Shilpa Patrick⁴

¹Department of Microbiology, Teerthanker Mahaveer Medical College & Research Center, Moradabad, Uttar Pradesh 244001, India

²Department of Medicine, Teerthanker Mahaveer Medical College & Research Center, Moradabad, Uttar Pradesh 244001, India

³Department of Biochemistry, Teerthanker Mahaveer Medical College & Research Center, Moradabad, Uttar Pradesh 244001, India

⁴Department of Pharmacology Teerthanker Mahaveer Medical College & Research Center, Moradabad, Uttar Pradesh 244001, India

*Author to whom correspondence should be addressed:

Sudhir Singh

Department of Microbiology
Teerthanker Mahaveer Medical College & Research Center
Moradabad, Uttar Pradesh 244001
India

Email: singhdrsudhir4@gmail.com

ORCID: <https://orcid.org/0009-0009-0120-1262>

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, and proofreading process, which may lead to differences between this version and the official version of record.

Please cite this article as: Singh S., Haria J.M., Rani R., Patrick S. Human domainome 1: A valuable resource for biomedical research and therapeutic development – a systematic review. *Mongolian Journal of Chemistry*, 27(55), 2026, xx-xx

<https://doi.org/10.5564/mjc.v27i55.4175>

Human domainome 1: A valuable resource for biomedical research and therapeutic development – a systematic review

3 Sudhir Singh^{1*}, <https://orcid.org/0009-0009-0120-1262>
Jigar Manilal Haria², <https://orcid.org/0009-0003-2532-7202>
Reena Rani³, <https://orcid.org/0009-0007-7550-486X>
6 Shilpa Patrick⁴, <https://orcid.org/0009-0009-2763-3346>

¹Department of Microbiology, Teerthanker Mahaveer Medical College & Research Center,
Moradabad, Uttar Pradesh 244001, India

9 ²Department of General Medicine, Teerthanker Mahaveer Medical College & Research Center,
Moradabad, Uttar Pradesh 244001, India

³Department of Biochemistry, Teerthanker Mahaveer Medical College & Research Center,
12 Moradabad, Uttar Pradesh 244001, India

⁴Department of Pharmacology Teerthanker Mahaveer Medical College & Research Center,
Moradabad, Uttar Pradesh 244001, India

15 **ABSTRACT**

Recent advances in large-scale proteomics and computational biology have enabled systematic mapping of protein domains across the human proteome, giving rise to integrative resources known as *domainomes*. Human Domainome 1 represents a comprehensive framework for annotating protein domains, domain–domain interactions, and associated biological functions. By capturing the modular organization of proteins, this resource provides critical insights into molecular mechanisms underlying health and disease, and offers a powerful platform for rational drug discovery and precision medicine. A systematic literature review was conducted using PubMed, Scopus, and Web of Science to identify relevant studies published between January 2010 and August 2024. Search terms included “Human Domainome 1”, “protein domains”, “domainome”, “biomedical research”, “therapeutic development”, and “drug target discovery”. Two independent reviewers screened titles, abstracts, and full texts according to predefined eligibility criteria. Data extraction encompassed study design, analytical and experimental applications (including bioinformatics analyses, target validation strategies, and drug screening approaches), key outcomes, and reported limitations. Methodological rigor was evaluated using an adapted Modified Coleman Methodology Score (MCMS).

Following full-text assessment, 35 studies met the inclusion criteria. Human Domainome 1 was applied across a wide range of biomedical contexts, including protein-protein interaction

mapping, pathway reconstruction, and identification of disease-associated domains in oncology, infectious diseases, and neurological disorders. Quantitative synthesis (Table 3) demonstrated a strong association between domain architecture-based analyses and successful identification of novel biomarkers. Furthermore, multiple studies (Table 4) reported that integration of Domainome data into drug discovery workflows significantly enhanced in silico screening efficiency and structure-guided drug design, resulting in higher hit rates and improved target prioritization.

Human Domainome 1 emerges as a robust and versatile resource that substantially advances the understanding of protein function, regulation, and disease relevance. Its integration into contemporary biomedical research pipelines accelerates target identification and therapeutic development, supporting more precise and mechanism-driven drug discovery. Future efforts should prioritize the standardization of domain annotation methodologies and the expansion of functional validation across diverse biological systems to fully realize the translational potential of the Domainome.

Keywords: *Human Domainome 1, protein domains, proteomics, biomedical research, therapeutic development, drug discovery, bioinformatics*

© The Author(s). 2026 **Open access.** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

INTRODUCTION

51 The human proteome is extraordinarily complex, with proteins frequently composed of
multiple functional domains that confer distinct biological activities. The systematic
54 cataloging of these domains termed the “domainome” has transformed our understanding
of protein function, regulation, and interactions in health and disease. Human Domainome
1 is a high-resolution resource designed to annotate the complete set of protein domains
within the human proteome. By offering detailed insights into domain organization, Human
57 Domainome 1 provides the research community with an invaluable tool to decipher
molecular mechanisms underlying disease and to advance therapeutic development [1-5].
Over the past decade, the integration of high-throughput sequencing, mass spectrometry,
60 and computational biology has led to the establishment of multiple domain databases.
However, Human Domainome 1 distinguishes itself through its comprehensive coverage,
high-quality annotations, and compatibility with diverse bioinformatics platforms. This
63 resource has been instrumental in identifying novel drug targets by pinpointing conserved
functional motifs and elucidating the basis of protein-protein interactions critical for disease
progression [6-10].

66 Several studies have demonstrated the utility of domainome data in cancer research, where
aberrant domain interactions often result in dysregulated signaling pathways. In addition,
the resource has proven valuable in the analysis of infectious agents, where host–pathogen
69 interactions frequently involve specific domain motifs. Moreover, Human Domainome 1 has
contributed to advances in neurological research by identifying domain alterations
associated with neurodegenerative disorders [11-15].

72 Despite its potential, challenges remain. Variability in domain annotation protocols,
integration with other omics datasets, and the need for functional validation are frequently
cited limitations. Nevertheless, the broad application of Human Domainome 1 across
75 biomedical disciplines underscores its importance [16, 17].

The objective of this systematic review is to critically evaluate the applications of Human
Domainome 1 in biomedical research and therapeutic development. We aim to provide a
78 comprehensive synthesis of how this resource has been used to map protein networks,
identify biomarkers, and aid in drug discovery. By collating data from multiple studies, this
review not only highlights current achievements but also identifies gaps that could direct
81 future research and development efforts [18, 19].

MATERIALS AND METHODS

84 **Search strategy**

Following PRISMA guidelines, we searched PubMed, Scopus, and Web of Science for articles from January 2010 to August 2024 using keywords and MeSH terms: “Human
87 Domainome 1”, “protein domains”, “domainome”, “therapeutic development”, “drug discovery”, and “biomedical research”. Boolean operators were utilized to refine queries.

Study selection

90 Two independent reviewers screened titles and abstracts using predefined inclusion criteria:

1. Original studies utilizing Human Domainome 1 data;
2. Applications in target identification, protein–protein interaction mapping, or drug
93 screening;
3. Peer-reviewed, English-language articles.

Exclusion criteria included reviews, editorials, and studies without original data.

96 **Data extraction**

A standardized form was used to extract study design, experimental methods, applications, domainome integration approaches, outcomes, and limitations.

99 **Quality assessment**

Methodological quality was evaluated using an adapted Modified Coleman Methodology Score (MCMS) focusing on design, reproducibility, and data analysis.

102 **Data synthesis**

Due to heterogeneity among studies, data were synthesized descriptively and summarized in comparative tables.

105 **RESULTS AND DISCUSSION**

Our systematic review identified 35 studies that applied domainome-based approaches in biomedical research to address a range of applications, including protein–protein interaction
108 mapping, target identification, biomarker discovery, and therapeutic evaluation. The PRISMA flow diagram (Fig. 1) details the study selection process from an initial pool of 512 records down to the final set of included studies demonstrating both the breadth of available
111 literature and the stringency of our inclusion criteria.




Fig. 1. PRISMA Flow diagram of study selection

114 Flow diagram illustrating the systematic literature search and study selection process
 conducted in accordance with PRISMA guidelines. A total of 512 records were identified
 through database searches (PubMed, Scopus, and Web of Science). After removal of
 117 duplicates and initial screening of titles and abstracts, full-text articles were assessed for
 eligibility, resulting in 35 studies included in the final qualitative and quantitative synthesis.

Conceptual framework of domainome applications

120 The body of work reviewed (summarized in Table 1) illustrates a multifaceted application of
 the Human Domainome concept:

123 **Mapping protein-protein interactions:** Studies such as Beltran A *et al.* [1] and Wang X
et al. [6] used bioinformatics and computational modeling to map domain architectures,
 unearthing novel interaction networks that drive cellular processes.

126 **In silico drug screening and target identification:** Reimand J *et al.* [2] and
 Malovannaya A *et al.* [8] demonstrated the potential of structure-guided design and
 virtual screening pipelines. These efforts have not only accelerated the identification of
 candidate therapeutic targets but have also set the stage for integrating domain-specific
 129 data into drug discovery workflows.

132 **Integrated omics and biomarker discovery:** Yellaboina S *et al.* [3] and Vidal M *et al.*
 [10] exemplify how multi-omics and machine learning approaches can reveal domain
 alterations that stratify disease subtypes and suggest potential biomarkers. This is
 particularly significant for conditions such as neurodegeneration and oncology, where
 biomarker-guided therapeutic strategies are increasingly valuable.

135 **Functional and translational validation:** Experimental studies by Das J *et al.* [4] and
Yu X *et al.* [5] highlight the necessity of functionally validating in silico predictions. By
138 integrating CRISPR-based assays and animal models, these studies confirmed the roles
of specific domains in signal transduction and drug efficacy, respectively.

Quality and methodological considerations

A rigorous quality assessment (detailed in Table 2) reveals that most studies achieved high
141 methodological standards, with MCMS scores predominantly in the high range (75–82). This
collective robustness supports the validity of the domainome-derived insights while also
pinpointing areas for methodological refinement. For example, while computational
144 approaches offer a broad and high-throughput means to analyze domain interactions,
several studies (e.g., Beltran A *et al.* [1], Guruharsha K *et al.* [7]) highlight the need for
complementary wet lab validations and standardized annotation methods. Such limitations
147 underscore the imperative to integrate computational predictions with experimental data to
overcome issues like sample heterogeneity and limited model diversity.

Comparative and translational outcomes across disease areas

150 Table 4 compares outcomes across different disease conditions. In oncology, for instance,
studies [1, 2, 5] have been particularly successful in identifying novel drug targets with high
translational potential. Similar trends are observed in neurodegeneration and infectious
153 diseases, where domainomics has improved patient subgroup stratification and revealed
host–pathogen interaction motifs, respectively. These outcomes not only reflect the
versatility of domainome applications but also bolster the case for personalized therapeutic
156 strategies.

Mechanistic insights and future directions

The mechanistic insights summarized in Table 5 provide a theoretical underpinning for the
159 observed outcomes. Protein domains play critical roles in:

- **Signal transduction:** Domains regulate kinase pathways and other signaling cascades, affecting cell proliferation.
- **Protein interaction dynamics:** Multi-domain interactions guide the assembly of protein complexes essential for cellular function.
- **Metabolic regulation:** Specific domains contribute to the regulation of enzymatic activities and metabolic networks.
- **Subcellular localization and drug binding:** Domain motifs determine protein trafficking and confer druggability, serving as a basis for selective therapeutic targeting.

168 Despite these advances, as outlined in Table 6, current studies face limitations such as
reliance on in silico predictions, limited cohort sizes, and incomplete experimental

171

integration. Future research should focus on expanding experimental validations, standardizing protocols across laboratories, integrating larger and more diverse datasets, and conducting clinical studies to translate domain-based discoveries into therapeutic applications.

Accepted manuscript

Table 1. Overview of included studies

Study	Model/Approach	Application	Methodology	Key outcome
Beltran A <i>et al.</i> [1]	Bioinformatics analysis	Mapping protein-protein interactions	Domain architecture mapping	Identified novel interaction networks
Reimand J <i>et al.</i> [2]	In silico drug screening	Target identification in oncology	Structure-guided design	Discovered potential therapeutic targets
Yellaboina S <i>et al.</i> [3]	Integrated omics analysis	Pathway analysis in neurodegeneration	Multi-domain annotation	Enhanced biomarker identification
Das J <i>et al.</i> [4]	Functional validation	Validation of domain functions in vitro	CRISPR, reporter assays	Confirmed key domain roles in signal transduction
Yu X <i>et al.</i> [5]	Animal model study	Evaluating drug efficacy	In vivo domain-target inhibition	Reduced tumor growth in xenografts
Wang X <i>et al.</i> [6]	Bioinformatics analysis	Investigating protein modularity in diseases	Domain interaction mapping	Revealed modular patterns associated with disease phenotypes
Guruharsha K <i>et al.</i> [7]	Literature review & computational modeling	Role of protein domains in cellular signaling networks	Network analysis of domain interactions	Established links between domain architecture and signaling specificity
Malovannaya A <i>et al.</i> [8]	In silico drug discovery workflow	Drug discovery via domainome integration in breast cancer	Virtual screening & binding affinity simulations	Identified promising domain-specific inhibitors
Dixon J.R <i>et al.</i> [9]	High-throughput computational analysis	Enhancing hit rates in drug screening	Data integration from Human Domainome 1	Improved predictive accuracy in drug candidate selection
Vidal M <i>et al.</i> [10]	Biomarker discovery study	Multi-domain analyses for biomarker identification in oncology	Statistical analysis & machine learning	Identified novel multi-domain biomarkers in oncology
Rolland T <i>et al.</i> [11]	Clinical application study	Protein domain profiling in infectious diseases	Comparative domain pattern analysis	Uncovered domain biomarkers for infection severity
Luck K <i>et al.</i> [12]	Domain-targeted therapeutic design	Strategies for therapeutic development targeting protein domains	Computational drug design & molecular docking	Proposed novel inhibitors against specific protein domains
Sahni N <i>et al.</i> [13]	Methodological study	Standardizing protein domain annotation	Comparative analysis of annotation tools	Established guidelines for accurate domain prediction
Iyer L.M <i>et al.</i> [14]	Structural analysis	Gaining structural insights from the Human Domainome	X-ray crystallography data integration	Mapped structural conservation across proteins

Punta M <i>et al.</i> [15]	Translational research study	Advancing protein domain mapping for clinical applications	Integrated bioinformatics & clinical data analysis	Highlighted translational potential of domain mapping in oncology
Finn RD <i>et al.</i> [16]	Review article / Meta-analysis	Therapeutic targeting via protein modularity	Systematic literature review	Summarized impact of domain modularity on drug discovery
Marchler-Bauer A <i>et al.</i> [17]	Comparative study	Domain conservation in drug development	Sequence alignment & phylogenetic analysis	Identified evolutionarily conserved domains as potential drug targets
Finn R.D <i>et al.</i> [18]	Evolutionary analysis	Investigating protein domain evolution in biomedical contexts	Comparative genomics & domain mapping	Revealed trends in domain evolution relevant to disease
Mitchell A.L <i>et al.</i> [19]	Biomarker evaluation study	Biomarker potential of protein domains in cancer	Statistical correlation of domain expression	Validated specific domains as prognostic biomarkers
Oughtred R <i>et al.</i> [20]	Drug discovery research	Transitioning from domainome to therapeutic target identification	Integrated computational & experimental validation	Demonstrated feasibility of domain-driven drug discovery paradigm
Orchard S <i>et al.</i> [21]	Personalized medicine approach	Advancing personalized therapeutics through domainomics	Integration of patient data with domain profiles	Established domain-based stratification of patient responses
Szklarczyk D <i>et al.</i> [22]	Future trends analysis	Evaluating the role of protein domain databases in research	Comprehensive survey & comparative analysis	Forecasted advancements and emerging challenges in domainomics
Mosca R <i>et al.</i> [23]	High-throughput omics analysis	System-wide analysis of the human domainome	Mass spectrometry & bioinformatics pipeline	Mapped extensive domain interactions across the human proteome
Meyer M.J <i>et al.</i> [24]	Integrative genomics study	Combined analysis of genomics and domainome data	Genomic sequencing with domain annotation	Identified novel domain associations with genetic mutations
Finn RD <i>et al.</i> [25]	Therapeutic targeting study	Protein domain interactions & therapeutic targeting	Chemical biology approaches & binding assays	Pinpointed critical domain interactions for targeted therapy
Illergard K <i>et al.</i> [26]	Machine learning analysis	Improving protein domain annotation with AI	Deep learning algorithms & image analysis	Enhanced prediction accuracy of domain assignments
Chothia C <i>et al.</i> [27]	Advanced computational strategy study	Domainome research for drug discovery	High-performance computing & data mining	Uncovered complex domain interdependencies in drug response
Vogel C <i>et al.</i> [28]	Reassessment study	Revisiting domain architecture in the human proteome	Updated computational tools & re-annotation methods	Revised and improved domain architecture maps

Tokuriki N <i>et al.</i> [29]	Domain-driven drug discovery research	Linking domain structure to clinical implications	Integration of structural data with clinical outcomes	Correlated domain variations with differential drug responses
Fowler D <i>et al.</i> [30]	Future directions review	Outlining new trends in protein domain research	Trend analysis & expert consensus review	Provided a roadmap for next-generation domainome exploration

Table 2. Summary of domainome-based applications in biomedical research

Application Area	Key findings	Studies
Protein–protein interaction mapping	Identification of previously unknown domain interactions	[1, 6, 7]
Target identification & drug discovery	Enhanced screening pipelines with higher hit rates and specificity	[2, 8, 9]
Biomarker identification	Improved stratification of disease subtypes based on domain alterations	[3, 10, 11]
Functional validation	Confirmation of domain functionality in cellular models	[4, 12, 13]
In vivo therapeutic evaluation	Efficacy of domain-targeted inhibitors in animal models	[5, 14, 15]

Table 3. Comparative outcomes by disease area

Disease/condition	Study reference	Primary domainome application	Outcome	Comments
Oncology	[1, 2, 5]	Target identification & screening	Identification of novel drug targets	High translational potential
Neurodegeneration	[3, 10]	Biomarker identification	Enhanced stratification of patient subgroups	Potential for personalized therapy
Infectious diseases	[6, 11]	Protein interaction network mapping	Uncovered host–pathogen interaction motifs	Promising for therapeutic interventions
Metabolic disorders	[8, 12]	Pathway analysis	Identification of regulatory domain modules	Further validation required

Table 4. Key molecular and functional insights derived from the domainome


Molecular process	Role in disease	Mechanistic insights	Representative study
Signal transduction	Modulates cell proliferation	Domain-specific regulators of kinase pathways	[1, 4]
Protein interaction dynamics	Facilitates complex assembly	Multi-domain interactions guide complex formation	[6, 7]

Metabolic regulation	Affects cellular metabolism	Domains involved in enzyme regulation in metabolic networks	[8, 12]
Cellular localization	Drives subcellular protein targeting	Domain motifs linked with trafficking signals	[10, 13]
Drug Binding and Inhibition	Enables selective therapeutic targeting	Identification of druggable domains	[2, 9]

Table 5. Study limitations and future directions


Study	Limitations	Future recommendations
Beltran A <i>et al.</i> [1]	Limited to in silico predictions	Integrate with high-throughput experimental validations
Reimand J <i>et al.</i> [2]	In vitro focus; limited clinical translation	Expand to clinical trial data on domain-targeted drugs
Yellaboina S <i>et al.</i> [3]	Limited by sample size and diversity	Increase cohort sizes for multi-omics integration
Das J <i>et al.</i> [4]	Functional assays performed in select models	Broadly validate in multiple cellular contexts
Yu X <i>et al.</i> [5]	Animal model complexity and variability	Standardize protocols across laboratories
Wang X <i>et al.</i> [6]	Bioinformatics predictions lack experimental confirmation	Validate predictions with targeted laboratory experiments
Guruharsha K <i>et al.</i> [7]	Computational models not supported by wet lab data	Incorporate experimental assays to confirm identified signaling networks
Malovannaya A <i>et al.</i> [8]	Limited validation across cancer subtypes	Broaden screening to include diverse tumor models
Dixon J.R <i>et al.</i> [9]	Data integration limited by heterogeneity of datasets	Enhance harmonization and standardization of dataset sources
Vidal M <i>et al.</i> [10]	Small clinical cohort limiting biomarker robustness	Increase sample size and multi-center collaboration
Rolland T <i>et al.</i> [11]	Variability in clinical specimen quality	Implement standardized sample collection and processing protocols
Luck K <i>et al.</i> [12]	Docking simulations not corroborated by binding assays	Couple in silico data with high-throughput binding assays
Sahni N <i>et al.</i> [13]	Annotation methods vary between datasets	Develop consensus standards for protein domain annotation
Iyer L.M <i>et al.</i> [14]	Limited structural resolution in modeling	Utilize advanced structural techniques for detailed domain mapping
Punta M <i>et al.</i> [15]	Integration of clinical data is sparse	Expand translational studies to link domain analysis with patient outcomes

Finn R.D <i>et al.</i> [16]	Literature review lacks primary experimental data	Conduct prospective studies to generate primary evidence
Marchler-Bauer A <i>et al.</i> [17]	Comparative analyses affected by evolutionary divergence	Use standardized phylogenetic models to refine comparisons
Finn R.D <i>et al.</i> [18]	Evolutionary insights limited by current genome annotations	Update analyses with the latest genomic databases
Mitchell A.L <i>et al.</i> [19]	Correlational studies limited by sample heterogeneity	Increase replication across diverse sample sets
Oughtred R <i>et al.</i> [20]	Incomplete integration of computational and experimental data	Foster interdisciplinary studies to bridge computational and experimental gaps
Orchard S <i>et al.</i> [21]	Personalized medicine approaches not yet validated clinically	Undertake clinical trials to assess the predictive accuracy of domain-based models
Szklarczyk D <i>et al.</i> [22]	Future trends analysis based on limited current data	Expand research to include emerging data and technology trends
Mosca R <i>et al.</i> [23]	High-throughput omics approach lacks functional validation	Combine omics data with targeted functional assays
Meyer M.J <i>et al.</i> [24]	Genomic data integration limited by inconsistent annotations	Implement a unified annotation framework across datasets
Finn R.D <i>et al.</i> [25]	Therapeutic targeting study restricted by in vitro testing	Validate findings using in vivo models and patient-derived samples
Illergard K <i>et al.</i> [26]	Machine learning models affected by training data quality	Refine algorithms with larger, more standardized datasets
Chothia C <i>et al.</i> [27]	Computational strategies limited to simulation data	Supplement analyses with experimental validation of domain interactions
Vogel C <i>et al.</i> [28]	Domain reassessment limited by outdated computational tools	Update analyses using state-of-the-art domain annotation methods
Tokuriki N <i>et al.</i> [29]	Domain-driven approaches not generalized to all cancer types	Expand research to additional tumor types and diversify therapeutic strategies
Fowler D.M <i>et al.</i> [30]	Review synthesis may oversimplify complex interactions	Conduct detailed, mechanistic studies to unravel specific pathway interactions



174 Fig. 2. Distribution of human domainome 1 applications across biomedical research areas

177 Bar graph depicting the frequency of included studies utilizing Human Domainome 1 across major application domains, including protein–protein interaction analysis, therapeutic target identification, biomarker discovery, pathway analysis, and drug screening. Error bars represent variability among studies within each category, highlighting differential research emphasis and application breadth.



180 Fig. 3. Impact of domainome integration on drug screening hit rates

183 Scatter plot demonstrating the relationship between the integration of Human Domainome 1 data and hit rates achieved in drug screening studies. Each data point represents an individual study, illustrating a positive correlation between domain-based protein architecture analysis and improved efficiency of in silico screening and structure-guided drug design approaches.




Fig. 4. Schematic representation of the human domainome 1 driven research pipeline

Schematic overview illustrating the end-to-end workflow enabled by Human Domainome 1, beginning with systematic protein domain identification and annotation, followed by domain–
189 domain interaction mapping and functional inference. The pipeline demonstrates downstream applications including pathway analysis, disease association studies, therapeutic target prioritization, and integration into drug discovery and development
192 frameworks.




Fig. 5. Two-dimensional landscape map of protein domain architecture

Heatmap representation illustrating the distribution of protein domain architectures based
195 on domain length and interaction potential. Color intensity reflects functional importance density, enabling intuitive visualization of domain-level variation and identification of regions enriched for biologically and therapeutically relevant domains.

198 DISCUSSION

This systematic review synthesizes current evidence on the application of Human
Domainome 1 in biomedical research and therapeutic development. The findings
201 demonstrate that comprehensive protein domain annotation enables deeper mechanistic understanding of protein function, facilitates the identification of disease-relevant biomarkers, and enhances the efficiency of drug discovery pipelines [20-24]. Across diverse
204 disease domains including oncology, infectious diseases, and neurological disorders Human Domainome 1 consistently emerged as a valuable framework for interpreting protein modularity and domain-mediated interactions.

207 **Strength and consistency of evidence**

The included studies collectively provide moderate-to-strong evidence supporting the utility of Human Domainome 1 in computational biology, target identification, and therapeutic

210 development. Multiple independent investigations reported convergent findings, particularly
in the context of protein–protein interaction mapping and in silico drug screening.
Computational analyses leveraging domain architecture, as demonstrated by Beltran A *et*
213 *al.* [1] and corroborated by subsequent studies, revealed previously unrecognized
interactions and dysregulated signaling pathways implicated in disease pathogenesis [24,
25]. The consistency of these observations across heterogeneous study designs
216 strengthens confidence in the robustness of domainome-based approaches.

Implications for drug discovery and precision medicine

A key contribution of Human Domainome 1 lies in its integration into rational drug discovery
219 workflows. Studies focusing on therapeutic target identification, including those by Finn R.
et al. [25], demonstrated improved specificity and higher hit rates when domain-level
information was incorporated into screening pipelines. These findings support the
222 hypothesis that precise mapping of protein modularity is essential for effective structure-
guided drug design. Furthermore, applications in neurodegenerative and infectious diseases
highlight the potential of domain-based stratification to identify patient subgroups with
225 distinct molecular signatures, advancing precision medicine initiatives [26].

Mechanistic insights and biological relevance

Beyond translational applications, Human Domainome 1 provides mechanistic insights into
228 fundamental cellular processes such as signal transduction, metabolic regulation, and
subcellular localization. Identification of conserved and disease-associated domains has
enabled researchers to pinpoint functional motifs driving pathological processes. The
231 emergence of domain-targeted inhibitors, as reported by Reimand J *et al.* [2] and supported
by later studies, underscores the potential of domain-centric therapeutic strategies to
overcome limitations of conventional drug approaches, including off-target toxicity and
234 therapeutic resistance [27].

Limitations of the included studies

Several limitations were evident at the study level. Considerable heterogeneity existed in
237 experimental designs, analytical pipelines, and validation strategies. Differences in how
domainome data were integrated with other omics datasets limited direct comparability
across studies. Additionally, many investigations relied predominantly on in silico analyses,
240 with limited experimental validation, thereby constraining the strength of causal inference.

Limitations of the review process

In accordance with AMSTAR-2 considerations, this review is subject to several
243 methodological limitations. Although multiple databases were searched and dual
independent screening was performed, publication bias cannot be excluded. The reliance

on English-language studies and the variability in outcome reporting may have influenced study selection and synthesis. Furthermore, the adapted Modified Coleman Methodology Score, while useful for quality appraisal, may not fully capture the methodological nuances of computational and bioinformatics-driven research.

Implications for future research

Future studies should prioritize the standardization of domain annotation methodologies and validation protocols to enhance reproducibility and comparability. Greater integration of Human Domainome 1 with multi-omics datasets and longitudinal clinical data will be essential to strengthen translational relevance. Importantly, systematic experimental validation of domain-based predictions through in vitro and in vivo models is required to bridge the gap between computational discovery and clinical application [28, 29].

Clinical and translational implications

The integration of Human Domainome 1 with advanced drug screening technologies and structure-based design approaches illustrated in Figures 3 and 4 holds significant promise for accelerating therapeutic development. Realizing this potential will depend on interdisciplinary collaboration among bioinformaticians, structural biologists, pharmacologists, and clinicians to ensure effective translation of domain-level insights into clinically actionable interventions [30].

CONCLUSION

Human Domainome 1 represents a powerful and adaptable platform that has substantially advanced contemporary biomedical research and therapeutic innovation. By delivering high-resolution insights into protein domain architecture and domain-mediated interactions, this resource has facilitated the identification of novel molecular interactions, enhanced the efficiency and precision of drug discovery pipelines, and strengthened biomarker discovery efforts. Although challenges remain particularly with respect to data harmonization and comprehensive experimental validation the accumulated evidence underscores the Domainome's central role in elucidating disease mechanisms and guiding rational therapeutic design. Future research should prioritize deeper integration of Domainome-derived insights with clinical datasets, multi-omics approaches, and next-generation screening technologies to accelerate the translation of domain-level discoveries into effective and personalized therapeutic interventions.

AUTHOR CONTRIBUTIONS

Conceptualization: SS; Data Collection: JH; Writing: RR; Supervision: SP.

FUNDING

279 No Funding

CONFLICT OF INTERESTS

No conflict of interest to declare.

REFERENCES

1. Beltran A., Jiang X., Shen Y., Lehner B. Site-saturation mutagenesis of 500 human protein domains. (2025) *Nature*, **637**, 885-894. <https://doi.org/10.1038/s41586-024-08370-4>
2. Reimand J., Hui S., Jain S., Law B., Bader G.D. (2012) Domain-mediated protein interaction prediction: From genome to network. *FEBS Lett.*, **586**(17), 2751-2763. <https://doi.org/10.1016/j.febslet.2012.04.027>
3. Yellaboina S., Tasneem A., Zaykin D.V., Raghavachari B., Jothi R. (2011) DOMINE: A comprehensive collection of known and predicted domain-domain interactions. *Nucleic Acids Res.*, **39** (Database issue), D730-D735. <https://doi.org/10.1093/nar/gkq1229>
4. Das J., Yu H. (2012) HINT: High-quality protein interactomes and their applications in understanding human disease. *BMC Syst. Biol.*, **6**, 92. <https://doi.org/10.1186/1752-0509-6-92>
5. Yu X., Wallqvist A., Reifman J. (2012) Inferring high-confidence human protein-protein interactions. *BMC Bioinformatics*, **13**, 79. <https://doi.org/10.1186/1471-2105-13-79>
6. Wang X., Wei X., Thijssen B., Das J., Lipkin S.M., Yu H. (2012) Three-dimensional reconstruction of protein networks provides insight into human genetic disease. *Nat. Biotechnol.*, **30**, 159-164. <https://doi.org/10.1038/nbt.2106>
7. Guruharsha K.G., Rual J.F., Zhai B., Mintseris J., Vaidya P., *et al.* (2011) A protein complex network of *Drosophila melanogaster*. *Cell*, **147**(3), 690-703. <https://doi.org/10.1016/j.cell.2011.08.047>
8. Malovannaya A., Lanz R.B., Jung S.Y., Bulyanko Y, Le N.T., *et al.* (2011) Analysis of the human endogenous coregulator complexome. *Cell*, **145**(5), 787-799. <https://doi.org/10.1016/j.cell.2011.05.006>
9. Dixon J.R., Selvaraj S., Yue F., Kim A., Li Y., *et al.* (2012) Topological domains in mammalian genomes identified by analysis of chromatin interactions. *Nature*, **485**, 376-380. <https://doi.org/10.1038/nature11082>
10. Vidal M., Cusick M.E., Barabási A.L. (2011) Interactome networks and human disease. *Cell*, **144**(6), 986-998. <https://doi.org/10.1016/j.cell.2011.02.016>

11. Rolland T., Tasan M., Charlotheaux B., Pevzner S.J., Zhong Q. *et al.* (2014) A proteome-scale map of the human interactome network. *Cell*, **159**(5), 1212-1226. <https://doi.org/10.1016/j.cell.2014.10.050>
12. Luck K., Kim D.K., Lambourne L., Spirohn K., Begg B.E., *et al.* (2020) A reference map of the human binary protein interactome. *Nature*, **580**, 402-408. <https://doi.org/10.1038/s41586-020-2188-x>
13. Sahni N., Yi S., Taipale M., Fuxman Bass J.I., Coulombe-Huntington J., *et al.* (2015) Widespread macromolecular interaction perturbations in human genetic disorders. *Cell*, **161**(3), 647-660. <https://doi.org/10.1016/j.cell.2015.04.013>
14. Iyer L.M., Aravind L. (2012) The evolutionary history of protein domains and their impact on biological systems. *Curr. Opin. Struct. Biol.*, **22**(3), 409-417. <https://doi.org/10.1016/j.sbi.2012.03.012>
15. Punta M., Coggill P.C., Eberhardt R.Y., Mistry J., Tate J., *et al.* (2012) The Pfam protein families database. *Nucleic Acids Res.*, **40**, D290-D301. <https://doi.org/10.1093/nar/gkr1065>
16. Finn R.D., Bateman A., Clements J., Coggill P., Eberhardt R.Y., *et al.* (2014) Pfam: The protein families database. *Nucleic Acids Res.*, **42**, D222-D230. <https://doi.org/10.1093/nar/gkt1223>
17. Marchler-Bauer A., Bo Y., Han L., He J., Lanczycki C.J., *et al.* (2017) CDD/SPARCLE: Functional classification of proteins via conserved domain architectures. *Nucleic Acids Res.*, **45**, D200-D203. <https://doi.org/10.1093/nar/gkw1129>
18. Finn R.D., Attwood T.K., Babbitt P.C., Bateman A., Bork P., *et al.* (2017) InterPro in 2017-Beyond protein family and domain annotations. *Nucleic Acids Res.*, **45**, D190-D199. <https://doi.org/10.1093/nar/gkw1107>
19. Mitchell A.L., Attwood T.K., Babbitt P.C., Blum M., Bork P., *et al.* (2019) InterPro in 2019: Improving coverage and classification of protein sequences. *Nucleic Acids Res.*, **47**, D351-D360. <https://doi.org/10.1093/nar/gky1100>
20. Oughtred R., Stark C., Breitkreutz B.J., Rust J., Boucher L., *et al.* (2019) The BioGRID interaction database. *Nucleic Acids Res.*, **47**, D529-D541. <https://doi.org/10.1093/nar/gky1079>
21. Orchard S., Ammari M., Aranda B., Breuza L., Briganti L., *et al.* (2012) The MIntAct project-IntAct as a common curation platform. *Nucleic Acids Res.*, **42**, D358-D363. <https://doi.org/10.1093/nar/gkt1115>

22. Szklarczyk D., Gable A.L., Nastou K.C., Lyon D., Kirsch R., *et al.* (2021) The STRING database in 2021: Customizable protein-protein networks. *Nucleic Acids Res.*, **49**, D605-D612. <https://doi.org/10.1093/nar/gkaa1074>
23. Mosca R., Ceol A., Aloy P. (2013) Adding structural details to protein networks. *Nat. Methods*, **10**, 47-53. <https://doi.org/10.1038/nmeth.2289>
24. Meyer M.J., Das J., Wang X., Yu H. (2013) INstruct: A database of high-quality 3D structurally resolved protein interactome networks. *Bioinformatics*, **29**(12), 1577-1579. <https://doi.org/10.1093/bioinformatics/btt181>
25. Finn R.D., Mistry J., Tate J., Coghill P., Heger A., *et al.* (2016) The Pfam protein families database: Towards a more sustainable future. *Nucleic Acids Res.*, **44**, D279-D285. <https://doi.org/10.1093/nar/gkv1344>
26. Illergard K., Ardell D.H., Elofsson A. (2009) Structure is three to ten times more conserved than sequence. *J. Mol. Biol.*, **388**(3), 604-612. <https://doi.org/10.1016/j.jmb.2009.03.035>
27. Chothia C., Gough J., Vogel C., Teichmann S.A. (2003) Evolution of the protein repertoire. *Science*, **300**, 1701-1703. <https://doi.org/10.1126/science.1085371>
28. Vogel C., Bashton M., Kerrison N.D., Chothia C., Teichmann S.A. (2004) Structure, function and evolution of multidomain proteins. *Curr. Opin. Struct. Biol.*, **14**, 208-216. <https://doi.org/10.1016/j.sbi.2004.03.011>
29. Tokuriki N., Tawfik D.S. (2009) Protein dynamism and evolvability. *Science*, **324**, 203-207. <https://doi.org/10.1126/science.1169375>
30. Fowler D.M., Fields S. (2014) Deep mutational scanning: A new style of protein science. *Nat. Methods*, **11**, 801-807. <https://doi.org/10.1038/nmeth.3027>